Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630884 · ClinicalTrials.gov registry record · Phase 1
Inflammatory Challenge and Fear
A Phase 1 study of Posttraumatic Stress Disorder (PTSD), sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 288
- Enrollment target
- 1
- Study location
NCT06630884 is a Phase 1 study of Posttraumatic Stress Disorder (PTSD) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 288 participants, above the 98-participant average among 17 other Posttraumatic Stress Disorder (PTSD) trials with a reported enrollment target (194% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06630884, a Phase 1 study of Posttraumatic Stress Disorder (PTSD), is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 288 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn if short-term changes in the immune system alter how we process information and experience fear. The main questions it aims to answer are: Do people who receive typhoid vaccine respond differently than those who receive a placebo saline vaccine? Do people who receive typhoid vaccine experience changes in how they think and feel? Participants will: Attend four appointments at the San Francisco VA Health Care System; Receive typhoid vaccine or placebo at one of the visits; Have their physiological responding measured while listening to sounds; Complete questionnaires and psychological tests.
Conditions Studied
Interventions
- BIOLOGICAL Typhoid VI Polysaccharide Vaccine Injectable Solution
- OTHER Saline Placebo (0.5mL injection)
Study Locations (1)
California
- San Francisco VA Health Care System - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06630884
The ClinicalTrials.gov registry entry for NCT06630884 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 98-participant average among 17 other Posttraumatic Stress Disorder (PTSD) trials with a reported enrollment target (194% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Posttraumatic Stress Disorder (PTSD) appearing as the primary indexed condition, and to 2 interventions - of which Typhoid VI Polysaccharide Vaccine Injectable Solution is the first listed.
NCT06630884 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06630884 about?
NCT06630884 is a clinical study titled "Inflammatory Challenge and Fear". The goal of this study is to learn if short-term changes in the immune system alter how we process information and experience fear. The main questions it aims to answer are: Do people who receive typhoid vaccine respond differently than those who receive a placebo saline vaccine? Do people who rece...
What is the current status of trial NCT06630884?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 288 participants. The study started on 2025-03-28. Estimated completion is 2028-11.
What conditions does trial NCT06630884 study?
This clinical trial studies the following conditions: Posttraumatic Stress Disorder (PTSD).
What interventions are being tested in trial NCT06630884?
The interventions under investigation include: Typhoid VI Polysaccharide Vaccine Injectable Solution (BIOLOGICAL), Saline Placebo (0.5mL injection) (OTHER).
Who is sponsoring clinical trial NCT06630884?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06630884 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Posttraumatic Stress Disorder (PTSD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acupuncture for the Treatment of Posttraumatic Stress Among Military Personnel
COMPLETED · Phase 1
-
Treatment for PTSD and Tinnitus
RECRUITING · NA
-
A Neurosensory Account of Anxiety and Stress (Study 2)
RECRUITING · NA
-
Augmenting Massed Cognitive Processing Therapy (CPT) to Prevent Suicide Risk Among Patients With PTSD
RECRUITING · NA
-
Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women
RECRUITING · NA
-
Integrated Treatment for Opioid Use Disorder and PTSD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.